Halozyme Therapeutics, Inc. (HALO) stock is up 53.26% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives HALO stock a score of 33 out of a possible 100. That rank is mainly influenced by a fundamental score of 25. In addition to the average rating from Wall Street analysts, HALO stock has a mean target price of $49.00. This means analysts expect the stock to add 15.21% over the next 12 months. HALO's rank also includes a long-term technical score of 36. The short-term technical score for HALO is 37.
Halozyme Therapeutics, Inc. (HALO) Stock Gains 1.36% This Week: Is It a Good Pick?
HALO has an Overall Score of 33. Find out what this means to you and get the rest of the rankings on HALO!